What Novo Nordisk's disappointing trial results mean for the obesity drug market Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme Novo Nordisk's next gen obesity drug outperforms Wegovy in late stage diabetes trial Reuters
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols